Brief: SCYNEXIS Reports Closing Of Exclusive License Agreement With GSK For Brexafemme
12/05/2023 13:43
May 12 (Reuters) - SCYNEXIS Inc SCYX.O :
* SCYNEXIS REPORTS CLOSING OF EXCLUSIVE LICENSE AGREEMENT
WITH GSK
FOR BREXAFEMME® (IBREXAFUNGERP TABLETS)
* SCYNEXIS INC- RECEIVING UPFRONT PAYMENT OF $90 MILLION
WITH
FUTURE PERFORMANCE-BASED MILESTONE PAYMENTS OF UP TO $503
MILLION AND TIERED ROYALTIES UNDER DEAL
* SCYNEXIS INC- UNDER LICENSE DEAL WITH GSK, CO RETAINS
RIGHTS TO
ALL OTHER ASSETS IN ITS PROPRIETARY CLASS OF
ENFUMAFUNGIN-DERIVED ANTIFUNGAL COMPOUNDS
Source text for Eikon: ID:nGNX3NYRWC
Further company coverage: SCYX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview